Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020

Nov. 10, 2020 21:05 UTC

 

 
 

LEXINGTON, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Marc Abrams, Ph.D., vice president of discovery research, will present an update on the Company’s early-stage development of extrahepatic RNAi therapeutics at TIDES Europe: Oligonucleotide & Peptide Therapeutics, a virtual conference taking place Nov. 11-13, 2020.

The presentation, titled, “Progress on a Pipeline of Extrahepatic RNAi Therapeutics,” includes nonclinical data demonstrating messenger RNA (mRNA) knockdown activity in multiple extrahepatic tissues using therapeutic nucleic acid modalities leveraging Dicerna’s proprietary RNAi technology. The presentation will be available from the conference website as part of the Oligonucleotide Discovery, Preclinical and Clinical track of TIDES Europe and will be viewable online for 30 days following the conference. The slides from the presentation will also be made available on the Events & Presentations page of Dicerna’s corporate website.

“Since introducing our proprietary GalXC™ technology four years ago, we have successfully advanced multiple candidates into clinical studies for genetically defined rare and prevalent diseases affecting the liver,” said Bob D. Brown, Ph.D., Dicerna’s chief scientific officer and executive vice president of research and development. “We are excited to continue this momentum by developing investigational therapies that leverage the flexibility of our proprietary RNAi technology, vastly increasing the scope of disease indications that may be targeted by RNAi. Research presented this week at TIDES Europe builds on the progress we reported earlier this year in extending our RNAi and oligonucleotide expertise to non-liver tissues. The additional evidence of RNAi-mediated reduction of target gene expression in a number of therapeutic pathways will help to inform and drive future research for pipeline expansion.”

The TIDES Europe conference will also feature an on-demand presentation and a live, moderated panel discussion focusing on Dicerna’s RNAi discovery and development collaboration with Novo Nordisk A/S. Dr. Brown and Christo Shalish, vice president of business development and alliance management, will participate in both forums. The discussion also will include Marcus Schindler, senior vice president, head of Global Drug Discovery, and John McDonald, corporate vice president, Global R&D Business Development of Novo Nordisk and will take place Thursday, Nov. 12, 2020 from 4:30 – 5:15 p.m. CET (10:30 – 11:15 a.m. ET).

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using our proprietary RNAi technology platform called GalXC™, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna’s GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on hepatocytes, Dicerna has continued to innovate and is exploring new applications of its RNAi technology beyond the liver, targeting additional tissues and enabling new therapeutic applications. In addition to our own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world’s leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegeneration and pain. At Dicerna, our mission is to interfere – to silence genes, to fight disease, to restore health. For more information, please visit www.dicerna.com.

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements pertaining to the Company’s planned attendance and presentation at a virtual scientific conference, which will include discussion of the Company’s progress with the development of extrahepatic RNAi therapeutics, our ability to create and develop investigational therapies, the potential of other indications that may be targeted by RNAi, as well as our business and operations, including the discovery, development and commercialization of our product candidates and technology platform, and the therapeutic potential thereof, the success of our collaboration with partners and any potential future collaborations. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those risks identified under the heading “Risk Factors” included in our most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.

GalXC™ is a trademark of Dicerna Pharmaceuticals, Inc.

Contacts

Media:
Amy Trevvett
+1 617-612-6253
atrevvett@dicerna.com

Investors:
Lauren Stival
+1 617-514-0461
lstival@dicerna.com

 
 

Source: Dicerna Pharmaceuticals, Inc.

Back to news